– USA, CT – Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company today announced the additions of Jim Mellon, Linda Kozick and Mark Simon to its Board of Directors, effective immediately.
About Jim Mellon
Mr. Mellon was one of the founders of Portage. Jim Mellon is an author, entrepreneur, and investor. He was one of the founders of Portage Biotech and is the co-author of five books, all written to identify emerging thematic trends leading to investment opportunities. He is a founder and Executive Director of Agronomics Limited (LSE: ANIC) an investment vehicle for cellular agriculture and cultivated meat. He has a particular interest in longevity research and is currently the co-founder and chairman of the anti-aging biopharma company Juvenescence. He is also a non-executive director of Condor Gold plc, the Executive Chairman of the Board of Manx Financial Group plc, Co-founder and Non-Executive Director of Bradda Head Lithium (LSE: BHL), and the non-executive Chairman of the Board of SalvaRx Group plc. He is also co-founder and Chairman of Endurance RP.
Mr. Mellon studied Philosophy, Politics & Economics at Oxford University.
About Linda M. Kozick
Linda Kozick has more than 25 years of experience in the biopharmaceutical industry, including 15 years of strategic commercial leadership in oncology with a focus on immuno-oncology. Before retiring she held leadership positions at Bristol Myers Squibb and was instrumental to Obdivo and Yervoy product management and portfolio strategy. In addition to Portage, she currently serves on the Board of Directors for RAPT Therapeutics, Inc. and Artiva Biotherapeutics.
Ms. Kozick received her B.S. in Medical Technology and M.S. in Molecular Immunology from SUNY Upstate Medical Center and her MBA from Chapman University.
About Mark Simon
Mark Simon has over 30 years of advising experience for biotech and pharma companies as an investment banker and research analyst. He is the Co-founder and an advisor of Torreya Capital, LLC, a global investment bank serving companies in the life sciences industry. Before co-founding Torreya Capital, LLC, he was a Managing Director and the head of life sciences investment banking at Citigroup, where he covered global biopharmaceutical companies, and also served as a Managing Director and Senior Biotechnology Research Analyst at Robertson Stephens. Mr. Simon serves on the boards of Cabaletta Bio and several disease advocacy and philanthropic foundations.
Mr. Simon holds a B.A. in History from Columbia College and an MBA from Harvard Business School.
About Portage Biotech Inc.
Portage is a clinical-stage immuno-oncology company advancing first-in-class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with evasive cancers. The Company’s access to next-generation technologies coupled with a deep understanding of biological mechanisms enables the identification of the most promising clinical therapies and product development strategies that accelerate these medicines through the translational pipeline. Portage’s portfolio consists of five diverse platforms, leveraging delivery by intratumoral, nanoparticles, liposomes, aptamers, and virus-like particles. Within these five platforms, Portage has 10 products currently in development with multiple clinical readouts expected over the next 12-24 months.
For more information: https://www.portagebiotech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.